Primsol Linked To Higher Risk Of Kidney Injuries When Used To Treat UTIs: Study

New research suggests that the antibiotic Primsol may not be the best treatment option for urinary tract infections, due to a risk of kidney injury and the development of dangerously high levels of potassium. 

While the antibiotic has been used mainly as a urinary tract infection treatment for decades, a study published last week in the medical journal The BMJ raises questions about this practice.

Primsol (trimethoprim) has been a commonly used antibiotic since the 1960s. It is available in generic form and is primarily used to treat urinary tract infections. It is also used to treat middle ear infections, pneumonia and Traveler’s diarrhea.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

In this new study, researchers from the U.K. looked at data on more than 178,000 individuals age 35 and over who were treated for urinary tract infections (UTIs) from April 1997 to September 2015. The subjects were treated with either Primsol, Cipro, Macrobid, amoxicillin or cefalexin. The drugs were used to treat more than 400,000 episodes of UTI during that time period among the subjects.

According to the findings, Primsol carried a 72% increased risk of acute kidney injury, and Cipro carried a nearly 50% increased risk, when compared to the other antibiotics. Additionally, Primsol more than doubled the risk of hyperkalemia; high levels of potassium which can cause muscle pain, numbness, abnormal heart rates, cardiac arrest and death.

Researchers determined that Primsol use resulted in two cases of additional incidents of acute kidney injury per 1,000 UTIs treated, and one to two additional cases of hyperkalemia, when compared to amoxicillin, which researchers used as a baseline.

However, the findings indicated there was no increased risk of death associated with Primsol, compared to the use of the other antibiotics, unless the patients were also taking renin-angiotensin system blockers, a class of drugs used to treat hypertension, in which case there was a slightly higher risk of death.

“Trimethoprim is associated with a greater risk of acute kidney injury and hyperkalaemia compared with other antibiotics used to treat UTIs, but not a greater risk of death,” the researchers concluded. “The relative risk increase is similar across population groups, but the higher baseline risk among those taking renin-angiotensin system blockers and potassium-sparing diuretics translates into higher absolute risks of acute kidney injury and hyperkalaemia in these groups.”

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Hair Relaxer Lawsuit Plaintiffs Tell Court Manufacturers Have Not Turned Over Complete Details on Toxic Products
Hair Relaxer Lawsuit Plaintiffs Tell Court Manufacturers Have Not Turned Over Complete Details on Toxic Products (Posted today)

Status report on hair relaxer lawsuits reveals that plaintiffs are still awaiting key information about the ingredients contained in specific hair straighteners sold by cosmetics manufacturers, as part of the discovery process leading up to early bellwether trials.

Suboxone Film Lawsuit Highlights How Dental Decay Problems Continue To Be Reported Even After Label Change
Suboxone Film Lawsuit Highlights How Dental Decay Problems Continue To Be Reported Even After Label Change (Posted yesterday)

Updated warnings issued in June 2022 failed to adequately convey Suboxone’s risks of tooth decay, which has resulted in continuing reports of dental problems among users of the film strips, lawsuit indicates.